Table of Contents
The American Hospital Association Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price Negotiation Program, formalizing the AHA Medicare Drug Price Negotiation comments on a rule with direct implications for how hospitals access negotiated drug pricing.
What the AHA Medicare Drug Price Negotiation Comments Recommend
The AHA recommended CMS require drug manufacturers to make the maximum fair price available through a point-of-sale mechanism and eliminate any option permitting manufacturers to meet their obligations through retrospective rebates or post-sale reconciliations. This recommendation centers on ensuring hospitals and other purchasers receive negotiated drug savings at the moment of purchase rather than having to wait for reimbursement after the fact.
Why Point-of-Sale Pricing Matters to Hospitals
A point-of-sale mechanism would mean hospitals pay the maximum fair price directly when acquiring negotiated drugs, avoiding the cash flow burden and administrative complexity that retrospective rebate systems can impose on purchasers who must first pay full price and later seek reimbursement.
The 340B Concern Behind These AHA Medicare Drug Price Negotiation Comments
The AHA expressed concerns that permitting retrospective MFP effectuation could set a foundation for broader manufacturer efforts to move the federal 340B program away from upfront discounts and toward a rebate-based model. This connection between the Medicare Drug Price Negotiation Program’s pricing mechanism and the separate 340B program reflects AHA’s concern that precedent set in one federal drug pricing program could spill over into how manufacturers approach pricing obligations elsewhere.
Why This Precedent Concern Matters
Given that 340B has already faced its own contentious battles over rebate versus upfront discount models, AHA’s warning suggests the association views this Medicare Drug Price Negotiation Program rule as a potential test case that manufacturers could later cite when advocating for similar rebate-based restructuring within 340B specifically.
The Call for National Standards Within These AHA Medicare Drug Price Negotiation Comments
The AHA also urged CMS to ensure that any future guidance or rulemaking regarding MFP availability maintains clear national standards and avoids permitting manufacturer-specific approaches that could create inconsistency across products and markets. This push for uniformity reflects a practical concern: without consistent national standards, hospitals could face a fragmented landscape where different manufacturers implement maximum fair price obligations differently, complicating purchasing, billing, and compliance processes across a health system’s full drug portfolio.
Why Manufacturer-Specific Variation Would Complicate Hospital Operations
Allowing individual manufacturers to determine their own approach to MFP availability could force hospitals to track and reconcile multiple different pricing and reimbursement processes simultaneously, adding administrative burden precisely where the Medicare Drug Price Negotiation Program was intended to simplify and standardize how negotiated drug savings reach patients and purchasers.
How This Fits Within Broader Medicare Drug Pricing Developments
This comment letter arrives amid a broader wave of Medicare Drug Price Negotiation Program activity, including CMS’s July 16 release of draft guidance for the 2028 negotiation cycle. AHA’s continued engagement across these successive regulatory actions suggests the association is tracking the program’s implementation closely as it moves from its initial negotiation rounds toward becoming a more permanent, codified feature of Medicare drug pricing policy.
Why Codification Itself Matters
CMS’s effort to codify the program in regulation, rather than continuing to operate primarily through guidance documents, represents a significant step toward making the Medicare Drug Price Negotiation Program’s rules more durable and legally binding, which is likely why AHA is pressing now to ensure the specific mechanics, particularly around point-of-sale pricing, are locked in favorably before the regulation is finalized.
What These AHA Medicare Drug Price Negotiation Comments Mean Going Forward
With AHA’s comments now formally submitted, CMS will need to weigh the association’s specific recommendations, point-of-sale pricing, avoiding retrospective rebates, and maintaining national standards, against manufacturer perspectives and other stakeholder input as it finalizes this codification rule. Given AHA’s explicit warning about potential spillover effects into the 340B program, hospitals and health systems participating in both the Medicare Drug Price Negotiation Program and 340B may want to monitor how CMS’s final rule addresses the point-of-sale versus rebate question, given its potential implications beyond this single program.
What to Watch Going Forward
As CMS works toward finalizing this codification rule, industry observers will likely watch whether the agency adopts AHA’s point-of-sale recommendation or permits manufacturers greater flexibility through retrospective rebate mechanisms. Given AHA’s specific concern about precedent-setting effects on the 340B program, hospital associations and 340B-participating providers may continue monitoring this rulemaking closely as a bellwether for how CMS approaches drug pricing mechanism design across its broader portfolio of federal drug pricing programs.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
